Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corporation demonstrates a strong outlook driven by impressive growth in its plasma segment, which achieved an organic growth rate of 20.2%, indicating a significant market share gain. Additionally, the adjusted operating margin within the plasma business increased by 60 basis points to 36.2%, reflecting effective cost management and operational efficiency across all segments. Furthermore, the company revised its free cash flow expectation to a range of $200-220 million, up from the previous forecast, underscoring robust financial health and enhanced cash generation capabilities.

Haemonetics Corp reported a significant decline in revenue, with a 19.6% decrease attributed to divestiture activities and a modest 2.8% organic growth, indicating challenges in sustaining overall sales growth, particularly within its blood center segment. The company's guidance for fiscal year 2026 suggests continued weakness, projecting reported revenue declines of 1% to 4% and only moderate organic growth, reflecting underlying pressures in key business areas. Moreover, the interventional technologies segment experienced a notable 11.6% organic decline, signaling a troubling trend in product demand that could further negatively impact future financial performance.